Reza Kafi, MD
Dermatology · Portland
- Medicare standing
- Clear
- Enrolled, allowed to bill and order, not excluded
- Plans that list them
- Not verified
- Not the same as out of network.
- Offices
- 3
Offices
3 locations · Providence Health and Services Oregon · Direct Dermatology Professionals PC
Hospitals listed: Providence Portland Medical Center. That is not proof they admit you there this week.
Plan participation
Not verified
We could not verify current plan participation for this doctor. This does not mean they are out of network. Call Dr. Kafi’s office to ask if they take your plan before you enroll.
California Medical Board record
Licence A84048 · Current
Licensed to practise in California · since 2003 · expires 2026-11-30 · University of Michigan Medical School.
No disciplinary actions, convictions, malpractice judgments or citations in this record.
Hospitals they work in
1 hospital
These rate the hospital, not this clinician. Most measures at most hospitals are no different from the national rate.
- Providence Portland Medical CenterPortland, ORAcute Care Hospital · Voluntary non-profit - Private · Has an emergency department · Birthing-friendlyPart of Providence, which runs 54 hospitals in 7 statesPatients rate it 4 of 5 · 77% would definitely recommend itOverall rating: 4 of 5 starsBetter than the national rate — Central Line Associated Bloodstream Infection (ICU + select Wards): 0.469, Oct 2024 – Sep 2025Better than the national rate — Clostridium Difficile (C.Diff): 0.318, Oct 2024 – Sep 2025Better than the national rate — Rate of emergency department (ED) visits for patients receiving outpatient chemotherapy: 3.3 (2.4 to 4.7) · 401 cases, Jan 2024 – Dec 2024
See every measure and the patient survey for Providence Portland Medical Center
Behind the star rating — Deaths: 0 better, 7 the same, 0 worse of 7 measures. Safety: 2 better, 6 the same, 0 worse of 8 measures. Readmissions: 1 better, 9 the same, 0 worse of 10 measures. The star rating is worked out from an earlier period than the measures below, so the two can disagree.
| Central Line Associated Bloodstream Infection (ICU + select Wards)Infections | 0.469 | Better | Oct 2024 – Sep 2025 |
| Clostridium Difficile (C.Diff)Infections | 0.318 | Better | Oct 2024 – Sep 2025 |
| Rate of emergency department (ED) visits for patients receiving outpatient chemotherapyUnplanned return visits | 3.3 (2.4 to 4.7) · 401 cases | Better | Jan 2024 – Dec 2024 |
| Abdominopelvic accidental puncture or laceration rateComplications and deaths | 1.23 (0.42 to 2.04) · 1,774 cases | No different | Jul 2022 – Jun 2024 |
| CMS Medicare PSI 90: Patient safety and adverse events compositeComplications and deaths | 0.92 (0.65 to 1.18) | No different | Jul 2022 – Jun 2024 |
| Death rate among surgical inpatients with serious treatable complicationsComplications and deaths | 154.26 (111.52 to 197) · 108 cases | No different | Jul 2022 – Jun 2024 |
| Death rate for COPD patientsComplications and deaths | 8.8 · 71 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart attack patientsComplications and deaths | 11.5 · 147 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart failure patientsComplications and deaths | 11.1 · 313 cases | None | Jul 2022 – Jun 2025 |
| Death rate for pneumonia patientsComplications and deaths | 14.5 · 211 cases | None | Jul 2022 – Jun 2025 |
| Death rate for stroke patientsComplications and deaths | 10.4 · 520 cases | None | Jul 2023 – Jun 2025 |
| Hybrid Hospital-Wide All-Cause Risk Standardized Mortality RateComplications and deaths | 3.2 · 4,878 cases | None | Jul 2024 – Jun 2025 |
| Iatrogenic pneumothorax rateComplications and deaths | 0.15 (0 to 0.35) · 5,800 cases | No different | Jul 2022 – Jun 2024 |
| In-hospital fall-associated fracture rateComplications and deaths | 0.25 (0.05 to 0.44) · 6,223 cases | No different | Jul 2022 – Jun 2024 |
| Perioperative pulmonary embolism or deep vein thrombosis rateComplications and deaths | 3.49 (1.71 to 5.28) · 2,035 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative acute kidney injury requiring dialysis rateComplications and deaths | 1.73 (0.32 to 3.14) · 1,168 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative hemorrhage or hematoma rateComplications and deaths | 2.13 (0.81 to 3.45) · 1,966 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative respiratory failure rateComplications and deaths | 6.68 (1.32 to 12.05) · 945 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative sepsis rateComplications and deaths | 7.18 (4.33 to 10.03) · 1,086 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative wound dehiscence rateComplications and deaths | 1.68 (0.32 to 3.05) · 710 cases | No different | Jul 2022 – Jun 2024 |
| Pressure ulcer rateComplications and deaths | 0.4 (0 to 0.97) · 5,053 cases | No different | Jul 2022 – Jun 2024 |
| Rate of complications for hip/knee replacement patientsComplications and deaths | 4.5 · 105 cases | None | Apr 2023 – Mar 2025 |
| Catheter Associated Urinary Tract Infections (ICU + select Wards)Infections | 0.905 | No different | Oct 2024 – Sep 2025 |
| MRSA BacteremiaInfections | 0.923 | No different | Oct 2024 – Sep 2025 |
| SSI - Abdominal HysterectomyInfections | 0.493 | No different | Oct 2024 – Sep 2025 |
| SSI - Colon SurgeryInfections | 0.757 | No different | Oct 2024 – Sep 2025 |
| Acute Myocardial Infarction (AMI) 30-Day Readmission RateUnplanned return visits | 15.7 · 342 cases | None | Jul 2023 – Jun 2025 |
| Heart failure (HF) 30-Day Readmission RateUnplanned return visits | 22 · 967 cases | None | Jul 2023 – Jun 2025 |
| Hospital return days for heart attack patientsUnplanned return visits | -11.8 · 160 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for heart failure patientsUnplanned return visits | 6.8 · 342 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for pneumonia patientsUnplanned return visits | -18.7 · 212 cases | None | Jul 2022 – Jun 2025 |
| Pneumonia (PN) 30-Day Readmission RateUnplanned return visits | 17.4 · 596 cases | None | Jul 2023 – Jun 2025 |
| Rate of inpatient admissions for patients receiving outpatient chemotherapyUnplanned return visits | 9.4 (7.4 to 11.9) · 401 cases | No different | Jan 2024 – Dec 2024 |
| Rate of readmission after hip/knee replacementUnplanned return visits | 5.8 · 122 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission for chronic obstructive pulmonary disease (COPD) patientsUnplanned return visits | 21.5 · 267 cases | None | Jul 2023 – Jun 2025 |
| Rate of unplanned hospital visits after colonoscopy (per 1,000 colonoscopies)Unplanned return visits | 14.1 (10.7 to 19.1) · 374 cases | No different | Jan 2022 – Dec 2024 |
| Ratio of unplanned hospital visits after hospital outpatient surgeryUnplanned return visits | 1.1 (0.8 to 1.4) · 461 cases | No different | Jan 2024 – Dec 2024 |
What patients said (443 patients answered, 20% of those asked)
| Cleanliness | 3 |
| Nurse communication | 4 |
| Doctor communication | 4 |
| Communication about medicines | 4 |
| Discharge information | 4 |
| Overall hospital rating | 4 |
| Quietness | 3 |
| Recommend hospital | 4 |
| Room was "always" clean | 66% |
| Nurses "always" communicated well | 79% |
| Doctors "always" communicated well | 81% |
| Staff "always" explained | 65% |
| Yes, staff "did" give patients this information | 90% |
| Yes, staff "did" give patients information about help after discharge | 90% |
| Doctors "always" explained things so they could understand | 76% |
| Doctors "always" listened carefully | 79% |
| Doctors "always" treated them with courtesy and respect | 87% |
| Patients who gave a rating of "9" or "10" (high) | 71% |
| Staff "always" explained new medications | 80% |
| Nurses "always" explained things so they could understand | 75% |
| Nurses "always" listened carefully | 76% |
| Nurses "always" treated them with courtesy and respect | 86% |
| "Always" quiet at night | 54% |
| "YES", patients would definitely recommend the hospital | 77% |
| Staff "always" explained possible side effects | 51% |
| Yes, staff "did" give patients information about possible symptoms | 91% |
Original Medicare doctor bills
$88,284
Medicare paid this office $88,284 for 583 people.
This is what Medicare paid the clinician — not Medicare Advantage, and not the pharmacy.
| Short return visit (20+ min) | 330 | $26,519 | $59 |
| Destruction of precancer skin growth, 1 growth | 249 | $12,893 | $42 |
| New patient visit (30+ min) | 142 | $8,592 | $61 |
| Return visit (30+ min) | 79 | $6,886 | $76 |
| Biopsy of related skin growth, first growth | 75 | $6,872 | $77 |
See all 11 services
| Short return visit (20+ min) | 330 | $26,519 | $59 |
| Destruction of precancer skin growth, 1 growth | 249 | $12,893 | $42 |
| New patient visit (30+ min) | 142 | $8,592 | $61 |
| Return visit (30+ min) | 79 | $6,886 | $76 |
| Biopsy of related skin growth, first growth | 75 | $6,872 | $77 |
| Destruction of precancer skin growth, 2-14 growths | 216 | $5,181 | $5 |
| New patient visit (45+ min) | 36 | $3,750 | $104 |
| Destruction of skin growth, 1-14 growths | 33 | $3,480 | $92 |
| Pathology examination of tissue using a microscope, intermediate complexity | 73 | $2,525 | $26 |
| Telephone, internet, or electronic health record assessment and management with written report by consulting physician, at least 5 minutes | 43 | $913 | $21 |
| Biopsy of related skin growth, each additional growth | 13 | $549 | $37 |
Procedures Medicare counted
| Melanoma (skin cancer) excision | 1-10 | None |
| Removal of skin lesions | 1521 | More than 96% of doctors who do this |
| Removal or shaving of skin growth | 1-10 | None |
| Skin biopsy | 294 | More than 90% of doctors who do this |
Who their Medicare patients are
583 Original Medicare patients in 2024. Average age 73 · Under 65 10% · 85 and older 13% · Women 40% · Also on Medicaid 24% · Health risk score 1.30. Sicker patients than 9 in 10 peers; the typical dermatology clinician is at 1.01.
Conditions among them: High blood pressure 64% · Diabetes 26% · Coronary heart disease 22% · Chronic kidney disease 22% · Depression 20% · Atrial fibrillation 19% · Heart failure 17% · Cancer 15% · COPD 13% · Dementia 8% · Stroke 7%.
The office billed $442,222, Medicare allowed $132,076 and paid $88,284; for 2,456 services of 37 kinds.
Original Medicare patients only. A risk score of 1.0 is the average Medicare patient; higher means sicker. Any count under 11 is hidden.
Year by year
| 2024 | 583 | 2,456 | 73 | 1.30 | $442,222 | $88,284 |
| 2023 | 550 | 2,408 | 73 | 1.19 | $419,855 | $85,519 |
| 2022 | 546 | 2,353 | 72 | 1.11 | $404,722 | $84,474 |
| 2021 | 651 | 2,536 | 71 | 1.23 | $444,088 | $95,631 |
| 2020 | 571 | 2,375 | 71 | 1.41 | $347,706 | $73,449 |
| 2019 | 351 | 2,610 | 73 | 1.21 | $369,479 | $83,980 |
| 2018 | 321 | 2,603 | 73 | 1.13 | $347,794 | $77,361 |
| 2017 | 29 | 133 | 70 | 0.76 | $22,716 | $5,523 |
| 2015 | 303 | 831 | 67 | 1.59 | $198,298 | $23,963 |
| 2014 | 418 | 1,379 | 68 | 1.29 | $301,666 | $41,798 |
| 2013 | 644 | 1,864 | 68 | 1.34 | $370,431 | $61,834 |
Original Medicare only. A service billed for fewer than 11 people in a year is hidden, so the lines can add up to less than the year's total.
See the services billed each year
2023: 11 services
| Short return visit (20+ min) | 332 | $24,509 | $56 |
| Destruction of precancer skin growth, 1 growth | 224 | $12,601 | $45 |
| Return visit (30+ min) | 95 | $8,257 | $75 |
| New patient visit (30+ min) | 101 | $7,124 | $71 |
| Biopsy of related skin growth, first growth | 73 | $6,225 | $73 |
| Destruction of precancer skin growth, 2-14 growths | 194 | $5,511 | $5 |
| New patient visit (45+ min) | 43 | $4,139 | $96 |
| Destruction of skin growth, 1-14 growths | 30 | $3,608 | $82 |
| Destruction of cancer skin growth of trunk, arms, or legs, 1.1-2.0 cm | 21 | $3,587 | $143 |
| Pathology examination of tissue using a microscope, intermediate complexity | 75 | $2,572 | $26 |
| Telephone, internet, or electronic health record assessment and management with written report by consulting physician, at least 5 minutes | 33 | $796 | $23 |
2022: 13 services
| Short return visit (20+ min) | 271 | $17,925 | $55 |
| Return visit (30+ min) | 115 | $11,221 | $79 |
| Destruction of precancer skin growth, 1 growth | 191 | $9,380 | $41 |
| New patient visit (30+ min) | 113 | $6,921 | $61 |
| Biopsy of related skin growth, first growth | 89 | $6,918 | $74 |
| Destruction of precancer skin growth, 2-14 growths | 166 | $5,343 | $5 |
| New patient visit (45+ min) | 38 | $4,661 | $123 |
| Destruction of skin growth, 1-14 growths | 26 | $3,721 | $81 |
| Destruction of cancer skin growth of trunk, arms, or legs, 1.1-2.0 cm | 23 | $3,485 | $134 |
| Pathology examination of tissue using a microscope, intermediate complexity | 87 | $3,028 | $29 |
| New patient visit (15+ min) | 38 | $1,739 | $46 |
| Biopsy of related skin growth, each additional growth | 13 | $655 | $44 |
| Telephone, internet, or electronic health record assessment and management with written report by consulting physician, at least 5 minutes | 16 | $426 | $27 |
2021: 13 services
| Short return visit (20+ min) | 243 | $16,799 | $54 |
| New patient visit (30+ min) | 199 | $13,783 | $69 |
| Return visit (30+ min) | 85 | $11,427 | $94 |
| Destruction of precancer skin growth, 1 growth | 184 | $10,232 | $43 |
| Biopsy of related skin growth, first growth | 82 | $7,352 | $77 |
| New patient visit (45+ min) | 68 | $7,271 | $107 |
| Destruction of precancer skin growth, 2-14 growths | 162 | $5,859 | $5 |
| Destruction of cancer skin growth of trunk, arms, or legs, 1.1-2.0 cm | 16 | $3,355 | $134 |
| Pathology examination of tissue using a microscope, intermediate complexity | 80 | $3,170 | $29 |
| Destruction of skin growth, 1-14 growths | 26 | $2,871 | $80 |
| New patient visit (15+ min) | 68 | $2,692 | $40 |
| Telephone, internet, or electronic health record assessment and management with written report by consulting physician, at least 5 minutes | 36 | $1,130 | $29 |
| Biopsy of related skin growth, each additional growth | 12 | $804 | $42 |
2020: 12 services
| Short return visit (20+ min) | 271 | $15,848 | $46 |
| Destruction of precancer skin growth, 1 growth | 168 | $8,430 | $39 |
| Biopsy of related skin growth, first growth | 96 | $7,130 | $68 |
| New patient visit (15+ min) | 162 | $7,111 | $44 |
| New patient visit (30+ min) | 109 | $7,055 | $65 |
| Destruction of precancer skin growth, 2-14 growths | 153 | $4,885 | $5 |
| Pathology examination of tissue using a microscope, intermediate complexity | 95 | $3,686 | $29 |
| Return visit (30+ min) | 32 | $2,633 | $69 |
| Destruction of cancer skin growth of trunk, arms, or legs, 1.1-2.0 cm | 14 | $2,201 | $122 |
| Destruction of skin growth, 1-14 growths | 25 | $2,106 | $81 |
| Telephone, internet, or electronic health record assessment and management with written report by consulting physician, at least 5 minutes | 29 | $958 | $31 |
| Biopsy of related skin growth, each additional growth | 18 | $932 | $44 |
2019: 13 services
| Short return visit (20+ min) | 209 | $14,294 | $49 |
| Destruction of precancer skin growth, 1 growth | 180 | $9,676 | $40 |
| Biopsy of related skin growth, first growth | 108 | $8,751 | $72 |
| New patient visit (30+ min) | 107 | $7,606 | $71 |
| Destruction of precancer skin growth, 2-14 growths | 172 | $6,002 | $4 |
| Pathology examination of tissue using a microscope, intermediate complexity | 109 | $4,076 | $29 |
| Destruction of cancer skin growth of trunk, arms, or legs, 1.1-2.0 cm | 22 | $3,769 | $140 |
| Return visit (30+ min) | 36 | $3,571 | $74 |
| Destruction of skin growth, 1-14 growths | 22 | $2,245 | $80 |
| Destruction of precancer skin growth, 15 or more growths | 15 | $1,942 | $108 |
| Biopsy of related skin growth, each additional growth | 25 | $1,324 | $44 |
| New patient visit (15+ min) | 24 | $1,069 | $45 |
| Short return visit | 13 | $376 | $25 |
2018: 13 services
| Short return visit (20+ min) | 176 | $13,762 | $53 |
| Biopsy of single growth of skin and/or tissue | 113 | $9,543 | $77 |
| Destruction of precancer skin growth, 1 growth | 163 | $9,363 | $42 |
| New patient visit (30+ min) | 101 | $7,327 | $73 |
| Destruction of precancer skin growth, 2-14 growths | 153 | $5,342 | $4 |
| Pathology examination of tissue using a microscope, intermediate complexity | 110 | $4,754 | $30 |
| Destruction of precancer skin growth, 15 or more growths | 21 | $3,050 | $113 |
| New patient visit (15+ min) | 63 | $2,897 | $46 |
| Destruction of cancer skin growth of trunk, arms, or legs, 1.1-2.0 cm | 15 | $2,677 | $134 |
| Destruction of skin growth, 1-14 growths | 25 | $2,550 | $82 |
| Return visit (30+ min) | 18 | $1,493 | $75 |
| Biopsy of each additional growth of skin and/or tissue | 27 | $854 | $27 |
| Short return visit | 19 | $712 | $34 |
2017: 2 services
| New patient visit (30+ min) | 14 | $1,221 | $87 |
| New patient visit (15+ min) | 12 | $611 | $51 |
2015: 8 services
| Short return visit (20+ min) | 189 | $8,361 | $34 |
| Destruction of precancer skin growth, 1 growth | 55 | $2,738 | $41 |
| Return visit (30+ min) | 28 | $2,571 | $60 |
| Short return visit | 78 | $1,322 | $17 |
| Biopsy of single growth of skin and/or tissue | 39 | $1,178 | $29 |
| Initial hospital care with straightforward or low level of medical decision making, per day at least 40 minutes | 14 | $1,123 | $80 |
| Destruction of skin growth, 1-14 growths | 18 | $653 | $36 |
| Destruction of precancer skin growth, 2-14 growths | 50 | $469 | $2 |
2014: 11 services
| Short return visit (20+ min) | 265 | $13,283 | $36 |
| Return visit (30+ min) | 39 | $5,305 | $58 |
| Destruction of precancer skin growth, 1 growth | 69 | $3,679 | $38 |
| Biopsy of single growth of skin and/or tissue | 66 | $2,413 | $34 |
| Destruction of skin growth, 1-14 growths | 38 | $2,335 | $60 |
| Short return visit | 86 | $1,855 | $19 |
| New patient visit (30+ min) | 25 | $1,367 | $55 |
| Initial hospital care with straightforward or low level of medical decision making, per day at least 40 minutes | 11 | $982 | $89 |
| Destruction of precancer skin growth, 2-14 growths | 57 | $753 | $2 |
| New patient visit (15+ min) | 19 | $625 | $33 |
| Biopsy of each additional growth of skin and/or tissue | 18 | $488 | $21 |
2013: 13 services
| Short return visit (20+ min) | 344 | $19,025 | $36 |
| New patient visit (30+ min) | 136 | $6,572 | $48 |
| Destruction of precancer skin growth, 1 growth | 111 | $5,965 | $40 |
| Return visit (30+ min) | 38 | $4,621 | $57 |
| Biopsy of single growth of skin and/or tissue | 105 | $3,714 | $34 |
| Destruction of skin growth, 1-14 growths | 55 | $3,650 | $49 |
| Short return visit | 147 | $2,993 | $17 |
| Initial hospital care with straightforward or low-level medical decision making at least 55 minutes | 19 | $2,226 | $117 |
| New patient visit (15+ min) | 74 | $2,197 | $30 |
| Destruction of precancer skin growth, 2-14 growths | 88 | $1,276 | $3 |
| Subsequent hospital care with moderate levelof medical decision making at least 35 minutes | 12 | $1,082 | $60 |
| Biopsy of each additional growth of skin and/or tissue | 19 | $372 | $20 |
| New patient visit (10+ min) | 15 | $227 | $15 |
Medicaid work
$164,403 in 2024
Medicaid paid $164,403 for 2,498 billed services this clinician did in 2024, up to 140 people in a month for one service.
Medicaid and CHIP claims where this clinician did the service, fee-for-service and managed care together. Any month with fewer than 11 patients is hidden, so small Medicaid practices undercount.
| OFFICE/OP CONSLTJ NEW/EST PT LOW MDM 30 MINUTES | 1,193 | $78,452 |
| OFF/OP CONSLTJ NEW/EST SF 20 | 886 | $59,129 |
| Short return visit (20+ min) | 294 | $19,032 |
| Return visit (30+ min) | 42 | $4,608 |
| New patient visit (30+ min) | 83 | $3,182 |
| 2024 | 2,498 | 5 | 140 | $164,403 |
| 2023 | 2,722 | 7 | 118 | $166,444 |
| 2022 | 2,788 | 7 | 146 | $173,565 |
| 2021 | 3,622 | 6 | 193 | $224,218 |
| 2020 | 3,519 | 7 | 253 | $209,067 |
| 2019 | 4,304 | 6 | 262 | $260,959 |
| 2018 | 5,114 | 6 | 355 | $355,438 |
See the largest Medicaid services in earlier years
2023
| OFFICE/OP CONSLTJ NEW/EST PT LOW MDM 30 MINUTES | 1,053 | $55,139 |
| Online digital evaluation and management service, for an established patient, for up to 7 days, cumulative time during the 7 days; 5-10 minutes | 575 | $48,790 |
| OFF/OP CONSLTJ NEW/EST SF 20 | 598 | $33,952 |
| Short return visit (20+ min) | 339 | $18,412 |
| Return visit (30+ min) | 59 | $5,462 |
| New patient visit (30+ min) | 85 | $4,689 |
| Alcohol and/or drug screening | 13 | $0 |
2022
| Online digital evaluation and management service, for an established patient, for up to 7 days, cumulative time during the 7 days; 5-10 minutes | 1,272 | $106,250 |
| OFFICE/OP CONSLTJ NEW/EST PT LOW MDM 30 MINUTES | 785 | $32,552 |
| OFF/OP CONSLTJ NEW/EST SF 20 | 442 | $19,678 |
| Return visit (30+ min) | 101 | $6,083 |
| New patient visit (45+ min) | 28 | $3,636 |
| New patient visit (30+ min) | 53 | $2,959 |
| Short return visit (20+ min) | 107 | $2,407 |
2021
| Online digital evaluation and management service, for an established patient, for up to 7 days, cumulative time during the 7 days; 5-10 minutes | 1,904 | $154,359 |
| OFF/OP CONSLTJ NEW/EST SF 20 | 651 | $31,699 |
| OFFICE/OP CONSLTJ NEW/EST PT LOW MDM 30 MINUTES | 870 | $28,761 |
| Return visit (30+ min) | 75 | $6,186 |
| New patient visit (30+ min) | 67 | $2,189 |
| Short return visit (20+ min) | 55 | $1,023 |
2020
| Online digital evaluation and management service, for an established patient, for up to 7 days, cumulative time during the 7 days; 5-10 minutes | 1,399 | $118,830 |
| OFF/OP CONSLTJ NEW/EST SF 20 | 1,308 | $72,602 |
| Online evaluation and management service provided by a physician or other qualified health care professional who may report evaluation and management services provided to an established patient or guardian, not originating from a related E/M service provided within the previous 7 days, using the Internet or similar electronic communications network | 115 | $9,775 |
| New patient visit (30+ min) | 79 | $5,275 |
| OFFICE/OP CONSLTJ NEW/EST PT LOW MDM 30 MINUTES | 496 | $1,977 |
| Short return visit (20+ min) | 73 | $385 |
| OFFICE/OUTPATIENT NEW SF MDM 15 MINUTES | 49 | $223 |
2019
| Online evaluation and management service provided by a physician or other qualified health care professional who may report evaluation and management services provided to an established patient or guardian, not originating from a related E/M service provided within the previous 7 days, using the Internet or similar electronic communications network | 2,393 | $187,545 |
| OFF/OP CONSLTJ NEW/EST SF 20 | 694 | $37,582 |
| OFFICE CONSULTATION | 342 | $22,509 |
| New patient visit (30+ min) | 120 | $9,739 |
| Short return visit (20+ min) | 40 | $1,900 |
| OFFICE/OP CONSLTJ NEW/EST PT LOW MDM 30 MINUTES | 715 | $1,683 |
2018
| Online evaluation and management service provided by a physician or other qualified health care professional who may report evaluation and management services provided to an established patient or guardian, not originating from a related E/M service provided within the previous 7 days, using the Internet or similar electronic communications network | 3,393 | $275,096 |
| OFFICE/OP CONSLTJ NEW/EST PT LOW MDM 30 MINUTES | 901 | $30,994 |
| OFF/OP CONSLTJ NEW/EST SF 20 | 356 | $22,217 |
| OFFICE CONSULTATION | 301 | $17,689 |
| New patient visit (30+ min) | 108 | $7,070 |
| Short return visit (20+ min) | 55 | $2,371 |
Drugs they prescribed that Part D paid
$828,650
Pharmacies billed $828,650 in 2024.
This is pharmacy cost, not the office bill, and not what patients paid.
Opioids were 0% of their Part D prescriptions (0 of 1,158) in 2024. At or below the middle of the specialty; the typical dermatology clinician is at 0%.
1,022 generic and 136 brand-name prescriptions · $828,650 in drug cost · 78 antibiotic prescriptions to 31 people.
Part D prescriptions only. The opioid rate is opioid prescriptions as a share of all this clinician's Part D prescriptions; surgeons and pain specialists run higher than others, so it is shown against the same specialty.
| Humira(Cf) | 74 | $513,831 | $6,944 |
| Taltz | 14 | $113,728 | $8,123 |
| Otezla | 18 | $87,830 | $4,879 |
| Dupixent | 12 | $42,991 | $3,583 |
| Clobetasol Propionate | 150 | $8,047 | $54 |
See all 19 drugs
| Humira(Cf) | 74 | $513,831 | $6,944 |
| Taltz | 14 | $113,728 | $8,123 |
| Otezla | 18 | $87,830 | $4,879 |
| Dupixent | 12 | $42,991 | $3,583 |
| Clobetasol Propionate | 150 | $8,047 | $54 |
| Triamcinolone Acetonide | 276 | $3,320 | $12 |
| Fluorouracil | 21 | $1,868 | $89 |
| Ketoconazole | 72 | $1,741 | $24 |
| Metronidazole | 40 | $1,688 | $42 |
| Fluocinolone Acetonide | 35 | $1,559 | $45 |
| Clindamycin Phosphate | 62 | $1,496 | $24 |
| Fluocinonide | 44 | $1,338 | $30 |
| Tretinoin | 17 | $1,317 | $77 |
| Betamethasone Dipropionate | 16 | $995 | $62 |
| Hydrocortisone | 97 | $851 | $9 |
| Doxycycline Hyclate | 31 | $587 | $19 |
| Minocycline | 32 | $568 | $18 |
| Mupirocin | 27 | $331 | $12 |
| Doxycycline Monohydrate | 11 | $321 | $29 |
Year by year
| 2024 | 1,158 | 428 | 0% (0) | 12% | $828,650 |
| 2023 | 1,075 | 385 | 0% (0) | 12% | $948,271 |
| 2022 | 990 | 384 | 0% (0) | 12% | $710,518 |
| 2021 | 1,272 | 446 | 0% (0) | 7% | $331,939 |
| 2020 | 1,075 | 372 | 0% (0) | 7% | $340,815 |
| 2019 | 899 | 353 | 0% (0) | 10% | $228,343 |
| 2018 | 756 | 343 | 0% (0) | 10% | $165,945 |
| 2017 | 1,126 | 319 | 0% (0) | None | $470,345 |
| 2016 | 1,283 | 311 | 0% (0) | 18% | $393,580 |
| 2015 | 1,284 | 329 | None | None | $398,035 |
| 2014 | 825 | 237 | None | 16% | $246,654 |
| 2013 | 492 | 145 | None | 17% | $125,366 |
Part D prescriptions only. A drug prescribed to fewer than 11 people in a year is hidden.
See the drugs prescribed each year
2023: 21 drugs
| Humira(Cf) | 68 | $489,790 | $7,203 |
| Humira | 13 | $94,364 | $7,259 |
| Otezla | 11 | $52,171 | $4,743 |
| Dupixent | 13 | $43,938 | $3,380 |
| Clobetasol Propionate | 128 | $13,984 | $109 |
| Fluocinonide | 57 | $4,562 | $80 |
| Triamcinolone Acetonide | 218 | $2,982 | $14 |
| Ketoconazole | 84 | $2,911 | $35 |
| Tretinoin | 11 | $2,008 | $183 |
| Metronidazole | 39 | $1,937 | $50 |
| Fluocinolone Acetonide | 34 | $1,910 | $56 |
| Clindamycin Phosphate | 36 | $1,347 | $37 |
| Fluorouracil | 16 | $1,346 | $84 |
| Hydrocortisone | 112 | $901 | $8 |
| Minocycline | 20 | $618 | $31 |
| Mometasone Furoate | 15 | $447 | $30 |
| Mupirocin | 34 | $332 | $10 |
| Doxycycline Hyclate | 13 | $299 | $23 |
| Hydroxyzine | 11 | $263 | $24 |
| Valacyclovir | 12 | $244 | $20 |
| Sulfamethoxazole-Trimethoprim | 11 | $71 | $6 |
2022: 17 drugs
| Humira(Cf) | 83 | $553,903 | $6,674 |
| Dupixent | 12 | $43,347 | $3,612 |
| Clobetasol Propionate | 93 | $9,300 | $100 |
| Ketoconazole | 104 | $3,721 | $36 |
| Triamcinolone Acetonide | 230 | $3,200 | $14 |
| Fluorouracil | 15 | $1,836 | $122 |
| Fluocinonide | 23 | $1,464 | $64 |
| Fluocinolone Acetonide | 22 | $1,217 | $55 |
| Clindamycin Phosphate | 29 | $1,149 | $40 |
| Metronidazole | 19 | $1,104 | $58 |
| Hydrocortisone | 110 | $857 | $8 |
| Doxycycline Hyclate | 14 | $557 | $40 |
| Mometasone Furoate | 12 | $511 | $43 |
| Doxycycline Monohydrate | 23 | $490 | $21 |
| Mupirocin | 37 | $331 | $9 |
| Minocycline | 11 | $286 | $26 |
| Glycopyrrolate | 18 | $269 | $15 |
2021: 23 drugs
| Humira(Cf) | 40 | $246,309 | $6,158 |
| Clobetasol Propionate | 92 | $5,952 | $65 |
| Triamcinolone Acetonide | 350 | $5,111 | $15 |
| Doxycycline Hyclate | 61 | $4,327 | $71 |
| Ketoconazole | 109 | $4,150 | $38 |
| Betamethasone Dipropionate | 28 | $3,415 | $122 |
| Fluocinonide | 54 | $2,805 | $52 |
| Clindamycin Phosphate | 48 | $1,810 | $38 |
| Tretinoin | 14 | $1,553 | $111 |
| Fluorouracil | 14 | $1,418 | $101 |
| Fluocinolone Acetonide | 22 | $1,282 | $58 |
| Metronidazole | 16 | $1,037 | $65 |
| Hydrocortisone | 120 | $917 | $8 |
| Minocycline | 21 | $851 | $41 |
| Mupirocin | 53 | $718 | $14 |
| Doxepin | 16 | $424 | $26 |
| Methotrexate | 16 | $394 | $25 |
| Hydroxyzine | 22 | $295 | $13 |
| Hydroxychloroquine Sulfate | 11 | $229 | $21 |
| Glycopyrrolate | 14 | $192 | $14 |
| Prednisone | 18 | $108 | $6 |
| Cephalexin | 11 | $75 | $7 |
| Terbinafine | 12 | $48 | $4 |
2020: 20 drugs
| Humira(Cf) | 26 | $145,298 | $5,588 |
| Humira | 13 | $74,800 | $5,754 |
| Clobetasol Propionate | 74 | $6,298 | $85 |
| Triamcinolone Acetonide | 304 | $4,789 | $16 |
| Ketoconazole | 75 | $3,038 | $41 |
| Fluocinolone Acetonide | 26 | $2,597 | $100 |
| Fluocinonide | 43 | $2,518 | $59 |
| Doxycycline Hyclate | 59 | $2,330 | $39 |
| Metronidazole | 29 | $2,015 | $69 |
| Betamethasone Dipropionate | 14 | $1,567 | $112 |
| Halobetasol Propionate | 13 | $1,442 | $111 |
| Minocycline | 23 | $929 | $40 |
| Clindamycin Phosphate | 35 | $840 | $24 |
| Hydrocortisone | 101 | $765 | $8 |
| Mometasone Furoate | 14 | $515 | $37 |
| Methotrexate | 14 | $352 | $25 |
| Mupirocin | 31 | $306 | $10 |
| Cephalexin | 14 | $188 | $13 |
| Valacyclovir | 12 | $183 | $15 |
| Prednisone | 20 | $112 | $6 |
2019: 19 drugs
| Humira(Cf) | 24 | $124,377 | $5,182 |
| Humira | 11 | $58,943 | $5,358 |
| Clobetasol Propionate | 46 | $4,400 | $96 |
| Triamcinolone Acetonide | 248 | $3,875 | $16 |
| Betamethasone Dipropionate | 25 | $3,804 | $152 |
| Ketoconazole | 85 | $3,206 | $38 |
| Fluocinonide | 37 | $3,019 | $82 |
| Tacrolimus | 14 | $2,315 | $165 |
| Metronidazole | 21 | $2,177 | $104 |
| Fluocinolone Acetonide | 24 | $2,017 | $84 |
| Halobetasol Propionate | 13 | $1,610 | $124 |
| Doxycycline Hyclate | 33 | $1,095 | $33 |
| Clindamycin Phosphate | 26 | $905 | $35 |
| Mometasone Furoate | 21 | $834 | $40 |
| Hydrocortisone | 100 | $775 | $8 |
| Hydroxyzine | 14 | $270 | $19 |
| Glycopyrrolate | 13 | $189 | $15 |
| Mupirocin | 17 | $174 | $10 |
| Prednisone | 12 | $62 | $5 |
2018: 14 drugs
| Humira | 20 | $97,833 | $4,892 |
| Clobetasol Propionate | 48 | $10,106 | $211 |
| Fluocinonide | 45 | $3,836 | $85 |
| Ketoconazole | 77 | $3,626 | $47 |
| Calcipotriene | 17 | $3,162 | $186 |
| Triamcinolone Acetonide | 156 | $2,254 | $14 |
| Clindamycin Phosphate | 37 | $2,047 | $55 |
| Metronidazole | 20 | $1,622 | $81 |
| Fluocinolone Acetonide | 16 | $1,326 | $83 |
| Doxycycline Hyclate | 32 | $995 | $31 |
| Mometasone Furoate | 34 | $983 | $29 |
| Hydrocortisone | 96 | $767 | $8 |
| Hydroxyzine | 21 | $736 | $35 |
| Mupirocin | 13 | $139 | $11 |
2017: 21 drugs
| Humira | 46 | $206,124 | $4,481 |
| Clobetasol Propionate | 90 | $23,672 | $263 |
| Fluocinonide | 127 | $14,751 | $116 |
| Calcipotriene | 23 | $6,863 | $298 |
| Betamethasone Dipropionate | 22 | $4,597 | $209 |
| Triamcinolone Acetonide | 217 | $4,065 | $19 |
| Clindamycin Phosphate | 49 | $3,149 | $64 |
| Metronidazole | 24 | $3,026 | $126 |
| Ketoconazole | 54 | $2,512 | $47 |
| Desonide | 15 | $2,095 | $140 |
| Doxycycline Hyclate | 19 | $1,507 | $79 |
| Fluocinolone Acetonide | 14 | $1,487 | $106 |
| Hydroxyzine | 57 | $804 | $14 |
| Hydrocortisone | 95 | $687 | $7 |
| Doxycycline Monohydrate | 21 | $546 | $26 |
| Mometasone Furoate | 20 | $495 | $25 |
| Ammonium Lactate | 20 | $470 | $24 |
| Doxepin | 11 | $416 | $38 |
| Mupirocin | 24 | $340 | $14 |
| Sulfamethoxazole-Trimethoprim | 20 | $163 | $8 |
| Prednisone | 16 | $127 | $8 |
2016: 25 drugs
| Stelara | 13 | $114,803 | $8,831 |
| Humira | 25 | $100,096 | $4,004 |
| Cosentyx Pen (2 Pens) | 12 | $47,908 | $3,992 |
| Fluocinonide | 238 | $29,712 | $125 |
| Clobetasol Propionate | 73 | $19,359 | $265 |
| Acitretin | 15 | $17,655 | $1,177 |
| Calcipotriene | 22 | $8,051 | $366 |
| Triamcinolone Acetonide | 222 | $4,740 | $21 |
| Ketoconazole | 94 | $3,707 | $39 |
| Betamethasone Dipropionate | 27 | $3,604 | $133 |
| Desonide | 21 | $3,570 | $170 |
| Clindamycin Phosphate | 48 | $2,960 | $62 |
| Urea | 13 | $1,896 | $146 |
| Fluorouracil | 12 | $1,768 | $147 |
| Metronidazole | 13 | $1,728 | $133 |
| Fluocinolone Acetonide | 12 | $1,626 | $135 |
| Tretinoin | 13 | $1,306 | $100 |
| Doxepin | 27 | $1,048 | $39 |
| Hydrocortisone | 122 | $829 | $7 |
| Doxycycline Monohydrate | 22 | $825 | $37 |
| Hydroxyzine | 68 | $563 | $8 |
| Mupirocin | 30 | $386 | $13 |
| Prednisone | 15 | $239 | $16 |
| Sulfamethoxazole-Trimethoprim | 12 | $215 | $18 |
| Cephalexin | 11 | $79 | $7 |
2015: 22 drugs
| Stelara | 12 | $136,074 | $11,340 |
| Humira | 18 | $58,782 | $3,266 |
| Humira | 13 | $41,129 | $3,164 |
| Fluocinonide | 257 | $34,055 | $133 |
| Clobetasol Propionate | 38 | $12,662 | $333 |
| Desonide | 27 | $5,413 | $200 |
| Triamcinolone Acetonide | 249 | $5,275 | $21 |
| Calcipotriene | 12 | $4,780 | $398 |
| Econazole Nitrate | 17 | $3,951 | $232 |
| Metronidazole | 26 | $3,507 | $135 |
| Fluorouracil | 16 | $2,968 | $185 |
| Fluocinolone Acetonide | 18 | $2,889 | $161 |
| Tretinoin | 23 | $2,886 | $125 |
| Clindamycin Phosphate | 38 | $2,611 | $69 |
| Ketoconazole | 69 | $2,301 | $33 |
| Doxepin | 52 | $1,664 | $32 |
| Hydroxyzine | 62 | $1,545 | $25 |
| Doxycycline Monohydrate | 28 | $963 | $34 |
| Hydrocortisone | 111 | $760 | $7 |
| Sulfamethoxazole-Trimethoprim | 26 | $532 | $20 |
| Prednisone | 25 | $196 | $8 |
| Cephalexin | 11 | $104 | $9 |
2014: 16 drugs
| Stelara | 13 | $132,562 | $10,197 |
| Humira | 15 | $40,753 | $2,717 |
| Fluocinonide | 197 | $17,983 | $91 |
| Desonide | 22 | $4,531 | $206 |
| Clobetasol Propionate | 23 | $3,882 | $169 |
| Fluocinolone Acetonide | 24 | $3,831 | $160 |
| Fluorouracil | 20 | $3,829 | $191 |
| Triamcinolone Acetonide | 136 | $3,369 | $25 |
| Clindamycin Phosphate | 23 | $1,489 | $65 |
| Tretinoin | 11 | $1,461 | $133 |
| Doxepin | 50 | $1,144 | $23 |
| Ketoconazole | 35 | $710 | $20 |
| Hydroxyzine | 39 | $530 | $14 |
| Hydrocortisone | 63 | $351 | $6 |
| Azathioprine | 16 | $274 | $17 |
| Hydroxychloroquine Sulfate | 16 | $237 | $15 |
2013: 9 drugs
| Humira | 23 | $51,477 | $2,238 |
| Fluocinonide | 114 | $7,922 | $69 |
| Triamcinolone Acetonide | 69 | $1,808 | $26 |
| Clindamycin Phosphate | 16 | $1,061 | $66 |
| Hydrocortisone | 54 | $908 | $17 |
| Doxepin | 42 | $803 | $19 |
| Hydroxyzine | 22 | $672 | $31 |
| Ketoconazole | 21 | $375 | $18 |
| Econazole Nitrate | 12 | $246 | $21 |
Money from drug and device companies
$125 in 2019
A payment is not proof that care is biased.
| Ortho Dermatologics a division of Bausch Health US | Duobrii | $125 | 1 payment
|
See the published payment
| Ortho Dermatologics a division of Bausch Health US | Meals · 2019-07-25 | Duobrii | $125 |
Checkups this office reported
Medicare did not publish checkup rates for this clinician.
- Medicare’s overall office score
- 87.8 / 100
- Scores the office’s reporting and systems. It is not a grade for how the doctor treats you.
Professional record
- NPI
- 1891737201
- Licence
- CA A84048, OR MD181659California A84048: Current · expires 2026-11-30
- Trained
- University of Michigan Medical School, 2002
- Group
- Providence Health and Services Oregon · Direct Dermatology Professionals PC
- Video visits
- Lists video visits
- Gender
- Male
More record details
- Sole proprietor
- No
- Taxonomy
- Federal specialty code 207N00000X (207N00000X)
- Mailing address
- Po Box 3158, Portland, OR, 97208
- NPI first listed
- 2006-06-11
- NPI last updated
- 2021-03-18
- NPI record certified
- 2021-03-18
This is when the NPI record was last certified, not a medical board exam.
Extra NPI addresses: 751 S Bascom Ave, San Jose, CA, 95128
This office lists an electronic records connection.